OR WAIT null SECS
Kevin Noonan is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s biotechnology and pharmaceuticals practice group.
Cell-based therapies are moving medical treatments forward, but intellectual property uncertainties may delay progress.
Treatment using cell-based therapies involves significant investment and, therefore, can be expected to have concomitantly significant costs to patients and their insurers. Accordingly, patent exclusivity will be important to defray high development and regulatory compliance costs.
The nature of such therapies, and recent patent law trends regarding natural products and methods relating to the practice of medicine, suggest these therapies may not be given the type of robust patent protection conventionally available for small-molecule drugs. The author discusses the impact of patent considerations for cell-based therapies.
BioPharm Internationalâ¨eBook: Development Strategies for Emerging Therapies
When referring to this article, please cite it as K. Noonan, " Patenting Prospects for Cell-Based Therapies," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).